These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 6809316)
1. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors. Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645 [TBL] [Abstract][Full Text] [Related]
3. [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption]. Yamada K; Takahama H; Nakai O; Takanashi T; Hosoya T Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2692-6. PubMed ID: 2506817 [TBL] [Abstract][Full Text] [Related]
4. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats. Cosolo W; Christophidis N Cancer Res; 1987 Dec; 47(23):6225-8. PubMed ID: 3119195 [TBL] [Abstract][Full Text] [Related]
5. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Neuwelt EA; Rapoport SI Fed Proc; 1984 Feb; 43(2):214-9. PubMed ID: 6692941 [TBL] [Abstract][Full Text] [Related]
6. Intracarotid infusion of hypertonic mannitol changes permeability of blood-brain barrier to methotrexate in rats. Pan GY; Liu XD; Liu GQ Acta Pharmacol Sin; 2000 Jul; 21(7):613-6. PubMed ID: 11360668 [TBL] [Abstract][Full Text] [Related]
7. [ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmoral mannitol]. Miyagami M; Kagawa Y; Tsubokawa T No Shinkei Geka; 1985 Sep; 13(9):955-63. PubMed ID: 2999632 [TBL] [Abstract][Full Text] [Related]
8. The effects of magnesium sulfate on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Kaya M; Gulturk S; Elmas I; Kalayci R; Arican N; Kocyildiz ZC; Kucuk M; Yorulmaz H; Sivas A Life Sci; 2004 Nov; 76(2):201-12. PubMed ID: 15519365 [TBL] [Abstract][Full Text] [Related]
9. Osmotic blood-brain barrier disruption: a new means of increasing chemotherapeutic agent delivery. Neuwelt EA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Hill SA; Lewis SE; Ehle AL; Beyer CW; Moore RJ Trans Am Neurol Assoc; 1979; 104():256-60. PubMed ID: 121949 [No Abstract] [Full Text] [Related]
10. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas]. Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082 [TBL] [Abstract][Full Text] [Related]
11. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378 [TBL] [Abstract][Full Text] [Related]
12. [Intra-arterial infusion of high dose methotrexate therapy in recurrent gliomas]. Hayashi A; Kyuma Y Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1461-6. PubMed ID: 2117886 [TBL] [Abstract][Full Text] [Related]
13. [Blood-brain barrier opening microcirculation in human brain tumor]. Sato S; Toya S; Otani M No To Shinkei; 1985 Feb; 37(2):109-13. PubMed ID: 2988587 [TBL] [Abstract][Full Text] [Related]
14. Osmotic blood-brain barrier disruption in the posterior fossa of the dog. Neuwelt EA; Glasberg M; Diehl J; Frenkel EP; Barnett P J Neurosurg; 1981 Nov; 55(5):742-8. PubMed ID: 6796658 [TBL] [Abstract][Full Text] [Related]
15. Technique of, and complications attributable to, repeated hyperosmotic blood-brain barrier disruption in dogs. Culver B; Inzana K; Jones J; Troy G; Kroll R; Culver B; Jortner B Am J Vet Res; 1998 Nov; 59(11):1503-10. PubMed ID: 9829415 [TBL] [Abstract][Full Text] [Related]
16. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648 [TBL] [Abstract][Full Text] [Related]
17. [The effect on the tumor vessel permeability by hyperosmotic blood brain barrier disruption]. Miyagami M; Tazoe M; Kagawa Y; Tsubokawa T No To Shinkei; 1988 Sep; 40(9):875-82. PubMed ID: 3142506 [TBL] [Abstract][Full Text] [Related]
18. Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification. Neuwelt EA; Pagel M; Barnett P; Glassberg M; Frenkel EP Cancer Res; 1981 Nov; 41(11 Pt 1):4466-70. PubMed ID: 6796261 [TBL] [Abstract][Full Text] [Related]
19. [Intra-arterial ACNU, CDDP chemotherapy for brain metastases from lung cancer: comparison of cases with and without intra-arterial mannitol infusion]. Iwadate Y; Namba H; Saegusa T; Sueyoshi K No Shinkei Geka; 1993 Jun; 21(6):513-8. PubMed ID: 8336809 [TBL] [Abstract][Full Text] [Related]